TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of “Buy” by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $10.90.

Separately, Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 20th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TLSI. Northern Trust Corp grew its holdings in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after buying an additional 5,936 shares in the last quarter. Bank of America Corp DE grew its holdings in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after buying an additional 178,298 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in TriSalus Life Sciences during the 1st quarter valued at about $55,000. Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences during the 1st quarter valued at about $187,000. Finally, Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares in the last quarter. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $4.84 on Friday. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $5.88. The stock’s 50-day simple moving average is $4.63 and its 200 day simple moving average is $5.09. The stock has a market capitalization of $241.37 million, a P/E ratio of -4.10 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The company had revenue of $11.21 million during the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. Equities research analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.